Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul;33(7):734-40.
doi: 10.1097/INF.0000000000000224.

Metabolic complications of in utero maternal HIV and antiretroviral exposure in HIV-exposed infants

Jennifer Jao  1 , Elaine J Abrams
Affiliations

Metabolic complications of in utero maternal HIV and antiretroviral exposure in HIV-exposed infants

Jennifer Jao et al. Pediatr Infect Dis J. 2014 Jul.

Abstract

Background: Despite a wide body of literature supporting the use of antenatal antiretrovirals (ARV) for the prevention of mother-to-child transmission, there remains a need for continued monitoring as the intrauterine interval is a critical period during which fetal programming influences the future health and development of the child.

Methods: We conducted a systematic review of the current literature addressing potential metabolic complications of in utero HIV and ARV exposure. We describe studies evaluating metabolic outcomes such as intrauterine and early postnatal growth, bone health and mitochondrial toxicity.

Results: Overall, infants exposed to HIV/ARV do not appear to exhibit vastly compromised intrauterine or early postnatal growth. However, some studies on the effect of combination antiretroviral therapy on small for gestational age and low birth weight outcomes in low-middle income countries show a risk for small for gestational age/low birth weight while those in the United States do not. Postnatal growth to 1 year does not appear to be affected by intrauterine tenofovir exposure in African studies, but a US study found statistically significant differences in length for age z scores (LAZ) at 1 year. Little data exists on long-term bone health. Mitochondrial toxicity including abnormal mitochondrial morphology and DNA content, as well as neurologic deficits and death, have been demonstrated in HIV/ARV-exposed infants.

Conclusion: Although gross measures of metabolic well-being appear to be reassuring, careful vigilance of even small risks for potential serious adverse effects to infants exposed to intrauterine HIV/ARVs is warranted as intrauterine fetal metabolic programming may substantially impact the future health of the child.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Studies Evaluating Multivariate Associations with VLBW, LBW and SGA in HIV/ARV-exposed Infants OR=Odds Ratio, CI=Confidence Interval, VLBW=Very Low Birth Weight (<1500 g), cART=Combination Antiretroviral Therapy, PI=Protease Inhibitor, LBW=Low Birth Weight (<2500 g), AZT=Zidovudine, ECS=European Collaborative Study, TDF=Tenofovir, SGA=Small for Gestational Age, NNRTI=Non-Nucleoside Reverse Transcriptase Inhibitor
See this image and copyright information in PMC

References

    1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173–1180. - PubMed
    1. Stek AM. Antiretroviral treatment in pregnancy. Curr Opin HIV AIDS. 2008;3:155–160. - PubMed
    1. Thorne C, Newell ML. The safety of antiretroviral drugs in pregnancy. Expert Opin Drug Saf. 2005;4:323–335. - PubMed
    1. Watts DH, Covington DL, Beckerman K, et al. Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy. Am J Obstet Gynecol. 2004;191:985–992. - PubMed
    1. Barker DJ. Rise and fall of Western diseases. Nature. 1989;338:371–372. - PubMed

Publication types

Substances